Veronika Kohlbrenner

Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I

Bengt I. Eriksson, O.E. Dahl, Lennart Ahnfelt et al. · Journal of Thrombosis and Haemostasis · 2004 · 202 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15

Genotypic Changes in Human Immunodeficiency Virus Type 1 Protease Associated with Reduced Susceptibility and Virologic Response to the Protease Inhibitor Tipranavir

John D. Baxter, Jonathan Schapiro, Charles A. Boucher et al. · Journal of Virology · 2006 · 132 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

James R. Seibold, Toby M. Maher, Kristin B. Highland et al. · Annals of the Rheumatic Diseases · 2020 · 80 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial

Joseph Gathe, David A. Cooper, Charles Farthing et al. · Clinical Infectious Diseases · 2006 · 77 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON

Yannick Allanore, Madelon C Vonk, Oliver Distler et al. · Annals of the Rheumatic Diseases · 2022 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13